Development programme
SYNCHRONIZE — survodutide
The phase 3 programme for the GLP-1 and glucagon receptor dual agonist survodutide in obesity and in metabolic dysfunction-associated steatohepatitis.
The phase 3 programme for the GLP-1 and glucagon receptor dual agonist survodutide in obesity and in metabolic dysfunction-associated steatohepatitis.
Sponsor class: Manufacturer-sponsored. First record: 2023.
Showing 0 records on this page
Records in this programme
11 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SYNCHRONIZE-1 | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| SYNCHRONIZE-2 | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| SYNCHRONIZE-CVOT | Survodutide | Phase 3 | Ongoing | Event-driven cardiovascular outcome trial | — | — | Not rated |
| SYNCHRONIZE-1-ADHERENCEprogramme record | Survodutide | Phase 3 | Ongoing | Observational | — | — | Very low |
| SYNCHRONIZE-1-BIOMARKERprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-1-ELDERLYprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-1-OLEprogramme record | Survodutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| SYNCHRONIZE-2-REGIONAL-CNprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-2-REGIONAL-JPprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-CVOT-PKprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| SYNCHRONIZE-CVOT-RENAL-IMPprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |